The Food and Drug Administration approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of certain adult patients with CD20-positive B-cell non-Hodgkin’s lymphoma and those with chronic lymphocytic leukemia.
The Food and Drug Administration (FDA) approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of adult patients with specific types of non-Hodgkin’s lymphoma (NHL) and those with chronic lymphocytic leukemia (CLL).
The biosimilar’s indications include treatment for:
This is the second biosimilar for Rituxan to be approved in the United States, and the 22nd biosimilar product to be approved by the FDA.
Biosimilar approvals are contingent on the fact that they are highly similar to a reference product, or a product that has already been approved by the FDA. These drugs must also be shown to have no clinically meaningful differences in safety or efficacy from the reference product.
Check back later for more information on what this approval means for patients.
FDA Biologics License Application Filed for Obe-Cel for Adult R/R B-ALL
November 29th 2023Following promising study results, a Biologics License Application has been filed with the FDA for obe-cel (obecabtagene autoleucel), a CAR-T cell therapy for patients with relapsed/refractory (r/r) adult B-cell acute lymphoblastic leukemia (ALL).
Read More